John M Flanagan

US Patent:

6326028, Dec 4, 2001

Filed:

Oct 30, 1998

Appl. No.:

9/183238

Inventors:

Thierry Nivaggioli - San Francisco CA
George Colegrove - San Diego CA
John Flanagan - Neshanic Station NJ

Assignee:

Monsanto Company - St. Louis MO

International Classification:

A61K 928
A61K 934
A61K 936

US Classification:

424481

Abstract:

This invention relates to coatings employed to coat medicinal tablets. Such tablets include but are not limited to small pellet(s) of medication to be taken orally. In particular this invention relates to the use of alginates and/or gellan gum, mixtures thereof and the like as tablet coatings. More in particular, this invention relates to the use of alginate and gellan gum as tablet coatings for tablets which are useful for humans including coating(s) on medicinal tablets and to a process for making such coatings.

US Patent:

20220193072, Jun 23, 2022

Filed:

Dec 13, 2021

Appl. No.:

17/548842

Inventors:

- New Haven CT, US
Andrew P. CREW - Chester CT, US
John FLANAGAN - Belmont MA, US
Sheryl Maxine GOUGH - Stratford CT, US
Marcia Dougan MOORE - Suffield CT, US
Yimin QIAN - Plainsboro NJ, US
Ian Charles Anthony TAYLOR - Madison CT, US
Jing WANG - Milford CT, US

International Classification:

A61K 31/497
A61P 35/04
A61K 31/519

Abstract:

The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I),or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R, R, R, R, m, and n are defined herein.

US Patent:

20230086457, Mar 23, 2023

Filed:

Apr 20, 2022

Appl. No.:

17/724987

Inventors:

- New Haven CT, US
Andrew P. Crew - Chester CT, US
Hanqing Dong - Madison CT, US
John J. Flanagan - Guilford CT, US

International Classification:

A61K 31/4166
A61K 31/381
A61K 31/495
C07D 401/04
C07D 401/14
C07D 417/14

Abstract:

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

US Patent:

20210275484, Sep 9, 2021

Filed:

Mar 9, 2018

Appl. No.:

16/492494

Inventors:

- Toronto, CA
- Oakland CA, US
John G. Flanagan - Berkeley CA, US
Karsten Gronert - Walnut Creek CA, US
Jessica Wei - Berkeley CA, US

International Classification:

A61K 31/202
A61K 31/557
A61P 25/28

Abstract:

Methods and compositions for inhibiting or preventing neurodegeneration, specifically hippocampal, cortical, and/or retinal ganglion cell neurons (RGC), and degeneration and/or cell loss or treating related disorders and diseases comprising administering to a subject an effective amount of one or more lipoxin compounds and/or lipoxin analogues such that degeneration and/or cell loss of neurons is inhibited or prevented.

US Patent:

20210060008, Mar 4, 2021

Filed:

Aug 24, 2020

Appl. No.:

17/001519

Inventors:

- New Haven CT, US
Andrew P. CREW - Guilford CT, US
John FLANAGAN - Belmont MA, US
Sheryl Maxine GOUGH - Stratford CT, US
Marcia Dougan MOORE - Suffield CT, US
Yimin QIAN - Plainsboro NJ, US
Ian Charles Anthony TAYLOR - Madison CT, US
Jing WANG - Milford CT, US

International Classification:

A61K 31/496
A61K 47/38
A61K 47/26
A61K 47/02
A61K 47/22
A61K 31/519
A61P 35/00

Abstract:

The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I),or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R, R, R, R, m, and n are defined herein.

US Patent:

20200249242, Aug 6, 2020

Filed:

Jul 19, 2018

Appl. No.:

16/632404

Inventors:

- BASEL, CH
- HERCULES CA, US
ROGER P. WALKER - HERCULES CA, US
JOHN FLANAGAN - HERCULES CA, US
JEANNETTE FAREH-MICHIEL - BASEL, CH

International Classification:

G01N 33/68
G16B 25/10

Abstract:

The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.

US Patent:

20190025303, Jan 24, 2019

Filed:

Oct 6, 2016

Appl. No.:

15/766525

Inventors:

- HERCULES CA, US
JOHN FLANAGAN - HERCULES CA, US
AUDREY ARJOMANDI - HERCULES CA, US
RAVI KAUL - HERCULES CA, US
STEVEN R. BINDER - HERCULES CA, US

International Classification:

G01N 33/569
C07K 14/20

Abstract:

The present invention relates to an immunoassay for the detection of specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.